Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kinetic Concepts' international sales surge as U.S. revenue dips

This article was originally published in The Gray Sheet

Executive Summary

International sales helped Kinetic Concepts Inc. achieve a 3.3% revenue gain in the first quarter over last year - to $485.8 million (or just below 1% at constant currency), the firm reported April 27. The total includes nearly $109.6 million in international sales, up 9.5% (or 1.3% at constant currency). But North American sales in KCI's Active Healing Solutions division, the company's largest, dipped 2% to $249.8 million during the quarter. A slowdown in U.S. demand for the firm's market-leading V.A.C. negative pressure wound therapy system was a factor behind the decline, CEO Catherine Burzik said, fueled in part by competition and more people either uninsured or on Medicaid due to high unemployment. The firm plans to fuel growth in part with a continued focus on Asian markets and new product launches, such as the next-generation V.A.C. Via, cleared by FDA in March. KCI's Regenerative Medicine division was one domestic bright spot, with U.S. sales of $78 million, up 18%. Globally, the latter division had revenue of $79 million, up 19.3%

You may also be interested in...



Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel